NVCR News and Press, NovoCure Limited From 02/23/23

Shares of the novel oncology company NovoCure (NASDAQ: NVCR) are trading lower today following the company's 2022 fourth-quarter and full-year results release this morning. Specifically, the Tumor Treating Fields product (TTFields) pioneer's stock was down by a hefty 7.36% on heavy volume...

Novocure Limited (NVCR) Q4 2022 Results Earnings Conference Call February 23, 2023, 08:00 AM ET Company Participants Ingrid Goldberg - Vice President of Investor Relations William Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ashley Cordova - C...

Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q4 2022 Earnings Call Feb 23, 2023 , 8:00 a.m. ET Ingrid Goldberg Continue reading For further details see: NovoCure (NVCR) Q4 2022 Earnings Call Transcript

The following slide deck was published by NovoCure Limited in conjunction with their 2022 Q4 earnings call. For further details see: NovoCure Limited 2022 Q4 - Results - Earnings Call Presentation

NovoCure press release ( NASDAQ: NVCR ): Q4 GAAP EPS of -$0.36 misses by $0.07 . Revenue of $128.43M (-3.6% Y/Y) beats by $1.23M . The United States, EMEA and Japan contributed $98.6 million, $17.0 million, and $7.9 million in quarterly net revenues, resp...

Dr. Ocean, a medical oncologist and Associate Professor of Clinical Medicine at Weill Cornell Medicine, brings decades of experience in oncology to Novocure Novocure (NASDAQ: NVCR) today announced that Allyson J. Ocean, M.D., has been elected to Novocure’s Board of Directors. ...

Full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million Pivotal LUNAR study in non-small cell lung cancer met primary overall survival endpoint and a key secondary overall survival endpoint Novocure completes enrollment of pivotal PANOVA-3 study...

NovoCure ( NASDAQ: NVCR ) is scheduled to announce Q4 earnings results on Thursday, February 23rd, before market open. The consensus EPS Estimate is -$0.29 and the consensus Revenue Estimate is $127.2M (-4.5% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward rev...

In the biotech world, investors often heave a sigh of relief when an important clinical goal is met. That was the case Wednesday with oncology specialist Novocure (NASDAQ: NVCR) , which enjoyed an almost 2% rise in its share price on the day, beating the S&P 500 index's 0.3% gain....

Final data from the PANOVA-3 study anticipated in 2024 Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in the pivotal PANOVA-3 study evaluating the efficacy of Tumor Treating Fields (TTFields) together with nab-paclitaxel and gemcitabine for treatment of...